Fusion Antibodies Plc (GB:FAB) has released an update.
Fusion Antibodies plc has issued 587,348 new ordinary shares to its non-executive directors as part of their compensation, aiming to manage cash flow effectively through the end of the financial year. This strategic move involves directors Simon Douglas, Colin Walsh, and Matthew Baker receiving shares at 4.15p each, reflecting the company’s efforts to maintain financial health while continuing its role in antibody discovery and development. The newly issued shares are set to commence trading on AIM, potentially drawing attention from investors keen on the biotech sector.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
